March 24, 2012 --In 2011, China life science transformed itself from an industry dominated by local, inward-looking domestic companies into a sector that has global impact, a change documented in a freely available ChinaBio® White Paper; Anaphore, a San Diego biotech startup, acquired Shanghai-based RuiYi Inc., a company with expertise in GPCRs; Qiagen will open a joint translational medicine lab with Bio-X Center of Shanghai Jiao Tong University; Fosun Pharma bought $35 million of Simcere Pharma’s shares, bringing its stake to 7.5%; Lilly wants to raise its China revenues from a current 2% up to 4% of the company’s total; Sihuan Pharma’s revenues rose 116% in 2011, winning tenders “in most regions and at stable price levels”; China Shijiazhuang Pharma (CSPC) is expanding into patented, innovative drugs; and Zhejiang Hisoar Pharma received approval to sell its API for meropenem in Japan. More details....
Stock Symbols: (NSDQ: QGEN) (SHE: 600196) (NYSE: SCR) (NYSE: LLY) (HK: 0460) (HK: 1093) (SHE: 002099)
